Fatty liver disease goes down with novel weight loss drugs, shows new study: What does this mean for therapy?
Importantly, around one in three patients also saw reduction in liver fibrosis or scarring of the liver that prevents it from functioning properly.
Metabolic dysfunction-Associated Steatotic Liver Disease (MAFLD) — until recently referred to as the Non-Alcoholic Fatty Liver Disease — is a chronic condition where there is an excessive build-up of fat on the liver. This fat accumulation leads to inflammation, scarring of the liver and may even cause liver cancer. The prevalence of MAFLD in India is estimated to be between 9% and 32%.
Dr SK Sarin, liver specialist and vice-chancellor of the Institute of Liver and Biliary Sciences, talks about the significance of the findings.
What do the results of the phase III trial tell us?
This is a very important study, which builds on the findings of the phase 2 trial on the impact of semaglutide on MASLD. Phase 2 trials are usually done to fix the dosing and the highest 2.4 mg dose of the medicine was used for the current trial. The results show that 62.9% of the people on semaglutide saw a loss of liver fat and inflammation as compared to 34.3% among people given placebo. The stiffening of the liver also reduced in 36.8% of the participants on semaglutide as compared to 22.4% on placebo.
The participants lost around 10% of their body weight in the current trial as compared to 14% recorded previously. All in all, the study shows promising results for fatty liver disease.
How does the drug work? Are these the effects of weight loss?
Semaglutide belongs to a class of medicines known as GLP-1 receptor agonists which mimic the action of certain gut hormones to improve secretion of insulin, inhibit secretion of glucagon that stimulates glucose production in the liver, and also reduce appetite by slowing down digestion. The study does not look into the confounding variable of weight loss, so we cannot say if there is any other reason for the improvements seen.
However, it is well-known that when people lose weight, MASLD improves. People who lose around 7-10% of their body weight, see a reduction in liver fat. And, with a weight-loss of more than 10%, they see regression in fibrosis. This happens even if people lose weight without using these drugs.
What is the current treatment for MASLD? What are the challenges?
The best way to treat MASLD is weight loss — be it with drug or with diet and exercise. The drug is meant for people who are not able to move and exercise or are unable to lose weight with diet and exercise. They come with several side effects such as vomiting, nausea, and even serious side effects such as stomach paralysis, inflammation of the pancreas, and thyroid cancer.
At present, there are three lines of treatment. One, of course, are the GLP-1 drugs that work on the gut hormones. Two, a drug called resmetirom that works on the thyroid hormone — this is again very expensive at around $ 5,400 a month. Third, FGF21 medicines that work on the adipose tissues. All of these medicines are meant to help with weight loss and thereby improve the liver.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 days ago
- Time of India
Experts: 4 out of 10 Indians hit by fatty liver, teetotallers also at risk
Bhubaneswar: Metabolic dysfunction-associated steatotic liver disease (MASLD), or fatty liver disease, is fast emerging as a major global health challenge, experts said at the Metabolic Horizon-2025 conference organised here on Saturday. They pointed out that four out of ten people in India are now affected by this condition. Many people still believe that only those who consume alcohol are at risk of developing fatty liver disease. However, experts warned that even teetotallers can suffer from fatty liver disease. "Fat gets deposited in the liver due to certain metabolic conditions, including diabetes, obesity, high cholesterol, negligible physical activity, and some diseases and drugs. Previously, when we found fat in the liver, we did not worry much. But once we discovered that MASLD is a common cause of cirrhosis, we began taking it seriously," said Dr Abhay Sahoo, an endocrinologist. Sahoo stated that initially, fat accumulates slowly in the liver, a condition known as hepatic steatosis. "After about five years, inflammation begins, and the liver becomes swollen. In the next stage, it progresses to fibrosis, which can eventually lead to cirrhosis. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Upto 15% Discount for Salaried Individuals ICICI Pru Life Insurance Plan Get Quote Undo We can reverse fatty liver in its early stage, but once fibrosis sets in, there is little chance of reversing the damage," he added. Sahoo said that people with fatty liver disease are usually asymptomatic. "They often do not experience any symptoms until the condition becomes severe. Some people may feel pain or discomfort on the right side of the abdomen. We often detect MASLD incidentally during an ultrasound or other tests," he said. Dr Satyajit Tripathy, a diabetologist, added that liver function tests (LFT), ultrasound scans, and even a fibroscan can help detect MASLD and assess liver elasticity. "This advanced test can detect fibrosis in the liver. A liver biopsy is another method to diagnose the disease," Tripathy said. He added that untreated MASLD can lead to more serious complications. "Exercises such as walking and yoga, along with dietary control and lifestyle changes, can help reverse this metabolic disorder if caught early. We need to maintain a healthy work-life balance and reduce fat accumulation, especially around the belly. A balanced diet is key to reducing liver fat. Even regular walking combined with a good diet can lower the risk of MASLD. Following a proper circadian rhythm is also important for a healthy lifestyle," said Tripathy.
Time of India
3 days ago
- Time of India
Why fatty liver disease is increasing even among non-drinkers: Check early symptoms, risk factors
Fatty liver disease, also known as hepatic steatosis, occurs when excess fat builds up in the liver. While some amount of fat in the liver is considered normal, too much can interfere with liver function and lead to serious complications. The condition is classified into two major types—Alcoholic Fatty Liver Disease (ALD) and Non-Alcoholic Fatty Liver Disease (NAFLD)—depending on the cause of fat accumulation. Alcoholic vs Non-Alcoholic: Key Differences As per Healthline, Alcoholic Fatty Liver Disease is caused by excessive and prolonged alcohol consumption. When not addressed, it can progress to alcoholic hepatitis and eventually cirrhosis, both of which cause permanent liver damage. Symptoms may include abdominal discomfort, fatigue, jaundice, and in severe cases, fluid accumulation and confusion. In contrast, Non-Alcoholic Fatty Liver Disease is not linked to alcohol use. Instead, it is closely associated with metabolic issues like obesity, insulin resistance, and high cholesterol. NAFLD can also progress from a simple fatty liver to Non-Alcoholic Steatohepatitis (NASH), a more serious condition involving inflammation and liver cell damage, potentially leading to fibrosis, cirrhosis, or even liver cancer. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like The New Honda City Sport Honda Book Now Undo The Silent Nature of the Disease Both ALD and NAFLD are often asymptomatic in early stages. Many people remain unaware they have liver damage until it has progressed significantly. In NAFLD, early warning signs may include persistent fatigue, upper right abdominal discomfort, and unexplained weight loss. Blood tests might show elevated liver enzymes, indicating inflammation or injury. When the disease advances to cirrhosis, symptoms can become more visible—yellowing of the skin (jaundice), swelling in the abdomen or legs, easy bruising, and mental confusion. Modern Lifestyle and Liver Stress NAFLD has become more prevalent due to sedentary lifestyles, poor dietary choices, stress, and sleep deprivation. Consumption of processed foods, sugary drinks, and lack of physical activity are considered major contributors. Medical experts warn that NAFLD is becoming one of the leading causes of liver-related complications globally. The liver plays a crucial role in detoxifying the body, processing everything from alcohol to medications to fatty food. When it's overburdened, the impact is felt throughout the body in the form of fatigue, digestive issues, hormonal imbalances, and more. Risk Factors to Watch While ALD is primarily caused by alcohol, its severity can be influenced by malnutrition, age, and underlying viral hepatitis. On the other hand, NAFLD risk increases with: Obesity or excess abdominal fat Type 2 diabetes or insulin resistance High triglycerides or low HDL cholesterol Sleep apnea, hypothyroidism, and polycystic ovary syndrome Rapid weight loss or malnourishment Older individuals are particularly vulnerable to both forms. What Can Be Done? For ALD, the cornerstone of treatment is complete abstinence from alcohol. Improvement is often seen once alcohol consumption stops. NAFLD requires a multifaceted approach: Weight loss through healthy diet and exercise Better control of blood sugar and cholesterol Avoiding processed and sugary foods Improving sleep quality Increasing physical activity, such as 30 minutes of walking daily Even modest weight loss—around 5–10% of body weight—can significantly improve liver health . Fatty liver disease is no longer an issue limited to heavy drinkers. With changing lifestyles, more people—regardless of their alcohol intake—are at risk. While the liver is a silent worker, its deterioration can have widespread effects. Early detection and lifestyle changes are critical for preventing long-term damage and ensuring overall well-being.
Time of India
3 days ago
- Time of India
This blood test can predict heart attack risk, and it's not cholesterol
While cholesterol levels are commonly used to assess heart disease risk, research shows that another blood marker—high-sensitivity C-reactive protein (hs-CRP)—may offer even more powerful insight, particularly when it comes to predicting heart attacks caused by silent inflammation. Heart attack risk and why the hs-CRP test helps predict it early C-reactive protein (CRP) is a substance produced by the liver in response to inflammation in the body. The high-sensitivity CRP (hs-CRP) test measures very low levels of CRP, helping detect chronic inflammation that may not cause obvious symptoms. Inflammation plays a central role in the development of atherosclerosis—a condition in which arteries become narrowed or blocked due to plaque buildup—raising the risk of heart attacks and strokes. According to the American Heart Association (AHA), individuals with elevated hs-CRP levels, even if their cholesterol appears normal, may still face significantly higher cardiovascular risk. Study confirms: hs-CRP predicts heart attack risk A major study called the JUPITER trial , published in the New England Journal of Medicine in 2008, provided strong evidence that measuring hs-CRP levels can help identify people at risk for heart attacks—even if their cholesterol is normal. In this large-scale study involving over 17,000 participants with normal LDL cholesterol but elevated hs-CRP levels, researchers found that treatment with a statin (rosuvastatin) cut the risk of heart attack by 54% and stroke by 48% compared to placebo. This demonstrated that inflammation—not just cholesterol—plays a critical role in cardiovascular risk. Interpreting hs-CRP levels and heart attack risk categories According to guidelines, hs-CRP levels fall into three major risk categories: <1.0 mg/L – Low cardiovascular risk 1.0–3.0 mg/L – Moderate risk >3.0 mg/L – High risk Even in the absence of high LDL cholesterol, values above 3.0 mg/L suggest a greater likelihood of vascular inflammation and arterial damage. How to lower hs-CRP and reduce heart risk Several lifestyle and medical interventions can help reduce hs-CRP levels: Adopt an anti-inflammatory diet (rich in fruits, vegetables, whole grains, and omega-3s) Exercise regularly (150+ minutes/week of moderate activity) Quit smoking Maintain a healthy weight Consider statin therapy if advised by a physician—particularly if both cholesterol and CRP are high Statins have been shown not only to lower LDL cholesterol but also to reduce inflammation markers like hs-CRP, as highlighted in the JUPITER trial. Cholesterol is just one piece of the cardiovascular puzzle. Measuring hs-CRP provides insight into hidden inflammation, helping to identify individuals at risk for heart disease—even if their standard lipid panel looks normal. For a more comprehensive cardiovascular assessment, ask your healthcare provider about getting an hs-CRP test alongside traditional cholesterol and Lipoprotein(a) testing. Also Read: Strength training for diabetes: How weight lifting helps manage type 2 diabetes
